Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence by Van Coevorden-van Loon, E.M.P. (Ellen M. P.) et al.
Vol.:(0123456789) 
J Neurooncol 
DOI 10.1007/s11060-017-2454-4
TOPIC REVIEW
Fatigue in patients with low grade glioma: systematic evaluation 
of assessment and prevalence
Ellen M. P. van Coevorden‑van Loon1,2 · Marijke B. Coomans2 · 
Majanka H. Heijenbrok‑Kal1,2 · Gerard M. Ribbers1,2 · Martin J. van den Bent3 
Received: 25 January 2017 / Accepted: 27 April 2017 
© The Author(s) 2017. This article is an open access publication
deeper insight in the underlying mechanisms of fatigue is 
essential in targeting therapy to individual patients.
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Introduction
Fatigue, characterized by feelings of tiredness, weakness 
and lack of energy, is the most frequently reported symp-
tom of cancer. In all different types of cancer fatigue is 
common, up to 99% of the patients experience fatigue dur-
ing the treatment and follow up [1–3]. Fatigue is the most 
important cause of loss of quality of life both for the patient 
and the care giver [4, 5]. Cancer-related fatigue is defined 
as a “persistent, subjective sense of tiredness related to can-
cer and cancer treatment that interferes with usual function-
ing” [6]. Despite its impact, fatigue in patients with can-
cer is underreported, underdiagnosed and undertreated [6]. 
Fatigue is a multidimensional concept. The National Com-
prehension Cancer Network (NCCN) has made an over-
view of coherent factors of the multidimensional concept of 
cancer-related fatigue, including: tumor-related factors and 
complications, comorbid conditions, psychological symp-
toms associated with the underlying tumor treatment, side 
effects of other medication, iatrogenic factors and psycho-
logical/behavioural factors [5].
This study focuses at patients with low grade glioma 
(LGG), defined as a grade I/II primary brain tumor aris-
ing from glial cells of the central nervous system includ-
ing astrocytoma, oligodendroglioma, ependymoma or 
mixed glioma (oligoastrocytoma) according to the World 
Health Organization (WHO) [7]. Patients suffering from 
LGG have a median life expectancy of 5–15 years thanks 
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to surgery, radiation and chemotherapy [2, 8–10]. There 
are few studies on the prevalence of fatigue in LGG 
patients. Proportions of fatigued in glioma patients vary 
from 39 to 77% [4, 11] which may be explained by dif-
ferences between assessment methods, patient popula-
tions, and definitions of fatigue.
With the increasing survival time there is a growing 
need for development and improvement of treatment pro-
grams for fatigue in LGG patients which should be based 
on the currently available evidence [12, 13]. Therefore, 
the current systematic review was set up (1) to evaluate 
how fatigue is assessed in LGG patients, (2) to assess 
the prevalence of fatigue.
Methods
A systematic search was performed in PubMed, Embase 
and PsychInfo in March 2016 using the search strategy 
presented in Table  1. After study selection, reference 
lists of all selected studies were examined.
Study selection
All titles and abstracts were screened independently 
by two investigators using the following criteria: (1) 
the study population included patients with suspected 
or confirmed LGG, (2) fatigue was reported as an out-
come measure, (3) patients were ≥18 years of age at the 
time of diagnosis and (4) the publication was an original 
full-length manuscript in a peer-reviewed journal, writ-
ten in English or Dutch. Studies including less than five 
patients and studies reporting duplicate data of previous 
studies were excluded. After a first selection of articles 
based on title/abstract, the full text manuscripts were 
retrieved and carefully assessed and evaluated accord-
ing to the in- and exclusion criteria (Fig. 1). In case the 
authors disagreed, a third reviewer was consulted.
Data extraction
After the final selection, two authors independently 
extracted data from the selected articles using a stand-
ard data extraction form. In case of disagreement, a third 
reviewer was consulted. Studies were differentiated in stud-
ies with fatigue as primary or secondary outcome (group 
1) and studies in which fatigue was only reported as a side 
effect of a (new) treatment therapy (group 2). In cases of 
missing data the corresponding authors were contacted 
by email [14–23]. The results of responding authors were 
included [14, 15, 21].
Data synthesis
The focus of this systematic review was to study instru-
ments used for the assessment of fatigue of patients with 
LGG in a qualitative way and to gain to more insight in the 
prevalence of fatigue. Therefore, the results of this review 
are presented in tables using descriptive statistics.
Results
The initial search identified 286 articles. After removal 
of duplicates in the three databases, the titles/abstracts of 
215 studies were evaluated according to the inclusion cri-
teria. A large number of articles (n = 107) were excluded 
because no LGG patients were included. Also, a relatively 
large number of articles were found to be abstracts of (oral) 
conference meetings (n = 24). Ultimately, 29 articles were 
screened in full text. The final dataset consisted of 19 arti-
cles that met all criteria. The characteristics of these studies 
are outlined in Table 2. A flowchart of the study selection is 
shown in Fig. 1.
Study population
Nineteen studies encompassed a total number of 917 LGG 
patients. Differentiation in type of glioma was reported 
for 886 patients (97%). The most common diagnosis was 
Table 1  Search strategy
Data source Search terms
Pubmed ((Glioma[mh] OR glioma*[tiab] OR astrocytoma*[tiab] OR ependymoma*[tiab] OR 
oligodendroma*[tiab]) AND (low grade*[tiab] OR grade I*[tiab] OR grade II*[tiab] OR grade 
1*[tiab] OR grade 2*[tiab] OR grade1*[tiab] OR grade2*[tiab])) AND ((fatigue*[tiab]))
Embase ‘glioma’/exp OR glioma OR ‘astrocytoma’/exp OR astrocytoma OR glioma*:ab,ti OR 
astrocytoma*:ab,ti OR ependymoma*:ab,ti OR oligodendroma*:ab,ti AND (‘low grade’:ab,ti 
OR ‘grade i’:ab,ti OR ‘grade ii’:ab,ti OR ‘grade 1’:ab,ti OR ‘grade 2’:ab,ti OR ‘grade1’:ab,ti 
OR ‘grade2’:ab,ti) AND fatigue*:ab,ti
PsychINFO (OR) glioma* astrocytoma* ependymoma* oligodendroma* (AND) (low grade) (AND) fatigue*
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astrocytoma (55%), followed by oligodendroglioma (22%), 
oligoastrocytoma (12%), ependymoma (9%) and other/
unknown type of LGG (2%). The mean age of the total 
population was 41.9  years. A description of the reported 
time post-diagnosis was available in 36% of the patients 
and ranged from 3.5 to 15  years. In 90% of the patients 
a complete description of treatment was provided. One 
study reported results prior to treatment [16]. In all other 
included studies, patients underwent some type of treat-
ment. Most of the patients underwent partial or complete 
surgery (80%), followed by radiotherapy (68%), chemo-
therapy (11%) or a combination. An overview of the study 
population characteristics reported in the included article is 
shown in Table 2.
Results
In 12 out of 19 studies fatigue was a primary or second-
ary outcome measure, defined as ‘Group 1’, represent-
ing 85% (n = 753) of all patients. In eight studies fatigue 
was reported in the outcome category measure of adverse 
events. In that category, it was reported as a side effect of a 
treatment under study. These studies are defined as ‘Group 
2’, representing 15% (n = 134) of all patients. One study 
Fig. 1  Flowchart of study 
selection Search
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measured fatigue both as a primary outcome and as a side 
effect of treatment [19].
Measurements
In group 1 seven self-assessment instruments could be 
identified. Two studies used two or more instruments [18, 
19]. Table 3 shows a short description and the internal con-
sistency of the measurement instruments.
Three multidimensional fatigue scales were used in the 
articles: (1) the Cancer Fatigue Scale (CFS), (2) the check-
list individual strength (CIS), and (3) the multidimensional 
fatigue inventory (MFI-20). The CFS consists of 15 items 
measuring physical, cognitive and activity-related fatigue 
[24]. One included study used the CFS [18]. The CIS 
consists of 20 items covering fatigue, fatigue severity (8 
items), concentration problems (13 items), reduced moti-
vation (4 items), and reduced activity (3 items) [25]. The 
CIS was used in one study [11]. The MFI-20 is a 20-item 
scale designed to evaluate five dimensions of fatigue: gen-
eral fatigue, physical fatigue, reduced motivation, reduced 
activity, and mental fatigue [26]. The MFI was used in 
one included study [14]. The CFS, CIS and MFI-20 are 
used across different patient populations, including cancer 
patients [1, 24, 26]. One unidimensional fatigue scale was 
used in the included articles: the brief fatigue inventory 
(BFI). The BFI is a nine-item instrument to assess fatigue 
on a rating scale. The BFI was developed for the rapid 
assessment of fatigue severity in cancer patients [27]. The 
scale was used in one article [18].
In three multidimensional instruments, fatigue was 
measured as a subdomain of health-related quality of life 
or mood: (1) The European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QLQ-C30), (2) The Functional Assessment of 
Cancer Therapy–Fatigue Scale (FACT–F) and (3) The 
Profile of Mood States (POMS). The European Organiza-
tion for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC QLQ-C30) is a quality-of-life scale 
that includes a three-item fatigue subscale which has been 
widely used as an independently validated fatigue measure 
across different oncological populations. It was specifically 
designed for use in oncology [28]. Five included studies 
used the EORT QLQ C30 [4, 16, 17, 29, 30]. The Func-
tional Assessment of Cancer Therapy–Fatigue (FACT–F) 
subscale is part of a collection of quality of life question-
naires targeting the management of chronic illness. It con-
sists of 13 items and is frequently used in cancer popula-
tions [31, 32]. The FACT–F was assessed in two included 
studies [18, 22]. The Profile of Mood States (POMS) con-
tains several scales including a fatigue subscale of seven 
items which have been used both in cancer and non-cancer Ta
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populations [33]. Two included studies used the POMS 
[19, 34].
In all studies reporting fatigue as side effect of treat-
ment, the National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI CTCAE) was used. The 
NCI CTCAE is a set of standardised definitions for adverse 
events and describes the severity of organ toxicity for 
patients receiving cancer therapy [35]. The NCI CTCAE 
describes fatigue as a disorder characterized by a state of 
generalized weakness with a pronounced inability to sum-
mon sufficient energy to accomplish daily activities. In this 
review, the identified articles used version 2.0, 3.0 or 4.0. 
The adverse events (AE’s) are defined based on grades one 
(mild), two (moderate), three (severe), four (life-threaten-
ing) and five (death related to AE).
Prevalence
In group 1, the prevalence of fatigue was provided in three 
studies representing 19% of the total of included patients 
(146/783) [4, 11, 29]. The reported prevalence of fatigue 
ranged from 39% (long term surviving LGG patients expe-
riencing severe fatigue) to 77% (feeling tired during the last 
week from “a little” to “very much”). Other results related 
to fatigue as an outcome measure were reported in 87% of 
the included patients (679/783). These results are shown in 
Table 4.
In group 2, a detailed description of fatigue as a side 
effect of treatment was provided in three studies, repre-
senting 54% (73/134) of the patients [36–38]. The reported 
prevalence as a side effect of treatment ranged from 20 
to 76% when fatigue was reported as a mild (grade 1) or 
moderate (grade 2), side effect. When reported as a severe 
(grade 3) side effect, fatigue was prevalent in 4% of the 
patients.
Discussion
This systematic review shows a variety of instruments that 
are used to measure fatigue in LGG patients. We identi-
fied seven self-assessment instruments (CFS, CIS, MFI, 
BFI, EORTC QOL-C30, FACT, POMS). All scales were 
used in a number of different cancer populations and have 
a good internal validity. Fatigue was the primary outcome 
only in two studies. In all other studies fatigue was a sec-
ondary outcome. When fatigue was reported as a side effect 
of treatment, the National Cancer Institute Common Termi-
nology Criteria for Adverse Events is uniformly used. This 
is in agreement with the recommendation of the National 
Cancer Institute [35].
Table 4  Prevalence and severity of fatigue
NR not reported, FG fatigue grade of toxicity, CT chemotherapy, IT immunotherapy, RT radiotherapy
a Reported prevalence on fatigue
Article Primary outcome study Reported results on fatigue LGG
Lee et al. [18] Fatigue NR
Struik et al. [11] Fatigue 39% severe  fatiguea
Cheng et al. [16] HRQoL NR
Dutzmann et al. [17] HRQoL NR
Gehring et al. [14] Cognitive functioning Above average score on scale “mental fatigue”
Gustafsson et al. [4] Function, HRQoL, coping 77% feeling tired during the last week from a little to “very much”a
Jakola et al. [29] Overall survival, HRQoL 44% experienced symptoms in at least one of the fatigue related 
 questionsa
Jones et al. [22] Functional performance measures post-surgery NR
Kiebert et al. [30] HRQoL Low median scores were found for fatigue
Shaw et al. [19] Cognitive functioning, mood, and QoL NR
Taphoorn et al. [34] QoL and cognitive functioning LGG patients scored higher on the subscales fatigue than did control 
subjects
Chamberlain et al. [36] Side effect of CT FG 1/2:20%
Duerinck et al. [20] Side effect of CT NR
Møller et al. [21] Side effect of CT NR
Pouratian et al. [37] Side effect of CT FG 1/2:76%
Taal et al. [23] Side effect of CT NR
Okada et al. [38] Side effect of IT FG 1:35%, FG 2:52%, FG 3:4%
Hauswald et al. [50] Side effect of RT NR
Maquilan et al. [51] Side effect of RT NR
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The EORTC QOL-C30 is the most frequently used 
instrument included in this review. Unidimensional instru-
ments or subscales measure the severity of perceived 
fatigue and tend to be short and easy-to-use. Also, they have 
the most robust psychometric data to support their use since 
they are widely used: the FACT and the EORTC QLQ-C30 
have been used in over 10.000 patients [39, 40]. However, 
fatigue is a multidimensional concept involving mood dis-
orders, anxiety, cognitive disorders and physical distress 
[5]. When the goal is to gain insight in fatigue, rather than 
only assess the level of perceived fatigue, a multidimen-
sional fatigue instrument provides a more comprehensive 
view [3]. This is line with the Dutch oncology guidelines, 
that recommend to use the multidimensional fatigue instru-
ment (MFI) for measuring cancer-related fatigue [41]. The 
MFI is considered to be the most frequently used multidi-
mensional fatigue instrument in clinical care in the Neth-
erlands and was found to be reliable, valid, easy to han-
dle and responsive [26, 39, 41, 42]. Additionally, it must 
be taken into account that even multidimensional fatigue 
instruments will only gain insight in the subjective experi-
ence of fatigue since fatigue is self-reported. The patient’s 
representations of their physical and cognitive functioning 
might not always correspond with objective measurement 
of physical activity, performance and cognitive functioning 
[43].
Fatigue is not only the most common symptom in cancer 
patients, but also a typical disabling symptom in neurologi-
cal disorders such as stroke [44]. One theory of fatigue in 
patients with traumatic brain injury and stroke patients is 
the ‘cognitive coping hypothesis’. This hypothesis states 
that patients with brain injury have to put in more effort to 
accomplish tasks, compared to non-injured individuals [45, 
46]. For patients, this means that they tire more easily and 
they need longer to recuperate from fatigue then before the 
injury [45]. We think this theory can be one of the explana-
tions for fatigue in LGG patients. Gehring et al. [15] found 
result that lower ratings of cognitive function in LGG 
patients were associated with self-reported mental fatigue, 
measured with the MFI. Research to analyse the factors 
of fatigue in low grade patients with subjective and objec-
tive measurement outcomes will be useful in developing 
individualized rehabilitation treatment programs in LGG 
patients with fatigue.
Because fatigue was a primary outcome in only two 
studies, we found limited information on prevalence rates. 
However, the included studies do show that fatigue seems 
to be a frequent problem prior to treatment [16], during 
radio- and chemotherapy [17, 30] and in the long term 
after treatment [11]. This is in line with patients with brain 
tumours of different origins than LGG [1, 47]. Unfortu-
nately, this review was not able to distinguish the different 
contributions in terms of fatigue from different treatment 
modalities. It can be stated that fatigue is a common side 
effect of these treatments, as is known from the literature 
[48]. Fatigue is both a frequent symptom of LGG as a side 
effects of its treatment and the relative effects of the dis-
ease versus treatment are difficult to distinguish. This is a 
major challenge in clinical decision making, weighing the 
benefits against the adverse effects of treatment. In newly 
diagnosed LGG patients the risks and benefits of treatment 
strategies including resection, radiation, chemotherapy or 
“watchful waiting” are recommended to be individually 
weighed [41, 49].
Conclusion
Despite the growing awareness of cancer-related fatigue, 
there is still a lack of knowledge of the exact pathophysiol-
ogy of fatigue and the underlying mechanisms of fatigue in 
LGG patients. This review shows that fatigue is a common 
problem in LGG patients, both as a disease symptom and as 
a side effect of treatment. Measurement of fatigue is com-
plex and multiple instruments need to be used for proper 
assessment. Incorporation of the patients’ perspective 
(patient reported outcome) with a multidimensional fatigue 
instrument is in line with the current guidelines. Addition-
ally, it must be taken into account that even multidimen-
sional fatigue instruments not yield sufficient insight in 
potential causes or consequences of fatigue, like a decrease 
in physical and cognitive performance. We suggest research 
to analyse the factors of fatigue in low grade patients with 
subjective and objective measurement outcomes to devel-
oping individualized rehabilitation treatment programs in 
LGG patients.
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